bathophenanthroline has been researched along with Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brabec, V; Kasparkova, J; Kostrhunova, H; Markova, L; Novohradsky, V; Trávníček, Z | 1 |
| Bonizzoni, M; Brown, SR; Cameron, CG; DeRegnaucourt, AR; Gray, JL; Hall, JF; Kim, Y; Lamb, RW; McFarland, SA; Oladipupo, OE; Papish, ET; Petersen, CM; Qu, F; Shrestha, AB; Thompson, MK; Ward, NA; Webster, CE; Xu, Y | 1 |
2 other study(ies) available for bathophenanthroline and Breast Neoplasms
| Article | Year |
|---|---|
An anticancer Os(II) bathophenanthroline complex as a human breast cancer stem cell-selective, mammosphere potent agent that kills cells by necroptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chloroacetates; Coordination Complexes; Cymenes; Female; Humans; Necroptosis; Necrosis; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Organoplatinum Compounds; Osmium; Phenanthrolines; Tumor Microenvironment | 2019 |
Light-responsive and Protic Ruthenium Compounds Bearing Bathophenanthroline and Dihydroxybipyridine Ligands Achieve Nanomolar Toxicity towards Breast Cancer Cells.
Topics: Breast Neoplasms; Female; Humans; Ligands; Phenanthrolines; Ruthenium; Ruthenium Compounds | 2022 |